HIK Hikma Pharmaceuticals Plc

TIDMHIK

RNS Number : 3602O

Hikma Pharmaceuticals Plc

08 February 2021

London, February 8, 2021 - Hikma Pharmaceuticals PLC (Hikma), will announce its preliminary financial results for the year ended 31 December 2020 on Thursday 25 February 2021.

A recording of the presentation will be available on the Company's website at www.hikma.com from 8:00am GMT. Hikma will also hold a live Q&A conference call for analysts at 10:00am GMT, and a recording will be made available on the Company's website later that day.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

 
Susan Ringdal 
 EVP, Strategic Planning and Global   +44 (0)20 7399 2760/ +44 7776 
 Affairs                               477050 
 

Teneo

Charles Armitstead +44 (0)7703 330 269

Camilla Cunningham + 44 (0) 7464 982426

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORKZGGZDRDGMZM

(END) Dow Jones Newswires

February 08, 2021 09:55 ET (14:55 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024